DSIP + Selank Sleep Research Stack

Delta sleep-inducing peptide (DSIP) was first isolated from rabbit cerebral venous blood in 1977 by Schoenenberger and colleagues at the University of Basel, who identified a nonapeptide capable of reliably eliciting high-amplitude delta waves in EEG recordings [PMID:196367]. Selank — a heptapeptide analogue of the immunomodulatory tetrapeptide tuftsin — was developed subsequently at the Institute of Molecular Genetics in Moscow, where researchers sought an anxiolytic compound that engaged the GABAergic system without the dependence liability of classical benzodiazepines. Pairing these two peptides addresses a common challenge in sleep research: improving sleep architecture during the night while maintaining clear, calm wakefulness during the day. DSIP operates at the sleep induction axis; Selank operates at the daytime anxiety axis. Together they form a chronobiologically coherent protocol in which the two pharmacological signals are temporally separated and mechanistically non-overlapping.

Why pair DSIP and Selank?

The rationale for combining DSIP and Selank rests on the observation that sleep disruption and daytime anxiety are frequently co-occurring states that reinforce one another. Excessive arousal during waking hours delays sleep onset and suppresses slow-wave sleep, while poor slow-wave sleep impairs the overnight restoration of GABAergic tone — perpetuating next-day anxiety. DSIP is administered pre-sleep to reinforce delta-wave architecture at its natural circadian peak; Selank is administered in the daytime to attenuate the hyperarousal that would otherwise prevent sleep onset in the evening.

Critically, the two peptides do not share a mechanism. DSIP acts through central peptide receptors and opioidergic modulation without directly binding benzodiazepine sites. Selank modulates GABAergic tone — specifically GABA-A receptor activity and enkephalin turnover — but does so without the allosteric positive-modulation of the benzodiazepine binding site, which accounts for its absence of observed tolerance or withdrawal in published animal-model literature [PMID:21503432]. This mechanistic decoupling means the two agents can be dosed on separate schedules without pharmacodynamic competition or additive CNS depression risk at the doses used in research.

Mechanism of action — each peptide

Summarised studies on the combination

No published peer-reviewed study has examined DSIP and Selank in direct co-administration in the same experimental preparation. The combination is studied here because both compounds have independent human Phase I/II research programmes in the Russian literature and because their mechanisms are temporally and pharmacodynamically compatible. The relevant evidence base for each is summarised below.

DSIP — key preclinical and early clinical findings:

The original Schoenenberger (1977) characterisation in rabbits [PMID:196367] established the EEG phenotype — reliable induction of high-amplitude delta oscillations — that has since been replicated in rat, cat and limited human EEG studies. Kovalzon and Strekalova (2006) reviewed the entire DSIP literature up to that date and noted that while the peptide's sleep-promoting effects in animal models are reproducible, the receptor-level mechanism remained unresolved, with evidence pointing to opioidergic interaction, somatostatin modulation, and direct action on hypothalamic sleep centres [PMID:16539667]. Graf et al. (1984) detected DSIP-like immunoreactivity in human milk, supporting physiological relevance of the peptide in human biology [PMID:6725499]. No large-scale randomised controlled trials in humans have been completed to date.

Selank — key preclinical and clinical findings:

Semenova et al. (2010) demonstrated anxiolytic effects in the elevated plus-maze paradigm, equivalent to diazepam at equipotent doses but without the motor impairment associated with benzodiazepines [PMID:21503432]. Kozlovskaya et al. (2006) documented pro-cognitive effects in rodents exposed to Selank, attributing the findings to tuftsin-receptor-mediated BDNF upregulation in hippocampus [PMID:16374622]. Sudakov et al. (2017) reported Selank efficacy in a post-traumatic stress paradigm in rodents, with sustained effects across a three-week dosing window [PMID:28853051]. In the Russian Federation, Phase II data supported the 0.15% nasal drop formulation for anxiety disorders; this dataset has not been published in full in peer-reviewed English-language journals, limiting independent evaluation.

The combination protocol described on this page is therefore extrapolated from the separate evidence bases for each compound. Researchers should treat the combination as unvalidated pending direct co-administration data.

Full research protocol

The dosing ranges below reflect the published animal-model literature, with Selank doses drawn from Russian Phase I/II data and DSIP doses scaled from rodent-to-human extrapolations commonly described in the peptide-research literature.

Weekly research timeline

• Week 1 (low-dose induction): DSIP begins at 100 µg SC to establish tolerability; Selank begins at 400 µg/day intranasal split across two administrations (AM and midday). The lower DSIP dose in week one avoids potential next-morning sedation while the research subject acclimatises to the peptide's delta-wave-promoting signal.
• Week 2 (full-dose phase): DSIP dose is doubled to 200 µg SC pre-bed. This is the primary research window for sleep-architecture data collection. Selank continues unchanged.
• Week 3 (taper): DSIP returns to 100 µg to allow gradual cessation. Selank continues at 400 µg/day throughout. A wash-out of 2–4 weeks is recommended before any subsequent cycle.

Reconstitution & storage notes

DSIP is supplied as a lyophilised powder and should be reconstituted with bacteriostatic water to a working concentration of 1 mg/mL (yielding 100–200 µg per 0.1–0.2 mL injection). Reconstituted DSIP solution is stable at 2–8 °C for approximately 21 days; beyond this window, sterility and peptide integrity cannot be assured. Repeated freeze-thaw cycles degrade the nonapeptide significantly — prepare aliquots before freezing if storage beyond 30 days is required.

Selank for research use is most commonly prepared as a 0.15% (1.5 mg/mL) intranasal solution in an isotonic phosphate-buffered saline vehicle, consistent with the Russian-approved formulation. This concentration delivers approximately 150 µg per 100 µL (one standard intranasal pump actuation). A 400 µg daily dose therefore requires approximately 2–3 actuations, typically divided between morning and midday administration windows. Selank is notably more metabolically stable than unmodified tuftsin — the three C-terminal residues slow enzymatic cleavage and extend the intranasal residence time. Store the intranasal preparation at 2–8 °C; discard open vials after 28 days.

Related research

If you are exploring this combination, you may also be interested in the Semax + Selank + Pinealon nootropic stack which pairs Selank with the ACTH-analogue Semax and the tripeptide Pinealon for a broader neuropeptide cognitive-and-mood protocol, or the Epitalon + Humanin + MOTS-c longevity stack which addresses circadian regulation and mitochondrial function from a longevity-research perspective.

For per-peptide monographs covering the full pharmacology of DSIP and Selank independently, see PeptideAuthority.co.uk/peptides/dsip and PeptideAuthority.co.uk/peptides/selank.